# Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

> **NCT07722754** · PHASE2 · RECRUITING · sponsor: **Guangdong Provincial People's Hospital** · enrollment: 160 (estimated)

## Conditions studied

- Colorectal Neoplasms Malignant
- Neoplasm, Metastatic

## Interventions

- **DRUG:** Cetuximab
- **DRUG:** Irinotecan
- **DRUG:** Bevacizumab
- **DRUG:** Sintilimab

## Key facts

- **NCT ID:** NCT07722754
- **Lead sponsor:** Guangdong Provincial People's Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2026-07-23
- **Primary completion:** 2028-07-31
- **Final completion:** 2029-01-31
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2026-09-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07722754

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07722754, "Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07722754. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*